Oyster Point Pharma, Inc. – NASDAQ:OYST

Market closed

Open in about 16 hours

+37.73%

quarter

+4.20%

year

Market Cap	N/A
Enterprise value	325.62M

P/E	-1.69
EV/Sales	16.62
EV/EBITDA	-1.98
Price/Sales	15.30
Price/Book	-13.49
PEG ratio	0.05
EPS	-7.11

Revenue	19.58M
EBITDA	-164.00M
Income	-188.97M
Revenue Q/Q	-68.84%
Revenue Y/Y	9.14%

Profit margin	-901.99%
Oper. margin	-809.09%
Gross margin	76.93%
EBIT margin	-809.09%
EBITDA margin	-837.45%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Oyster Point Pharma, Inc. (NASDAQ:OYST): Profit margin
Dec 2021	6.59M	-44.67M	-677.29%
Mar 2022	2.70M	-50.95M	-1884.54%
Jun 2022	4.69M	-53.09M	-1131.43%
Sep 2022	5.59M	-40.24M	-719.76%

Oyster Point Pharma, Inc. (NASDAQ:OYST): Earnings per share (EPS)
2022-02-24	-1.39	-1.61
2022-05-05	-1.74	-1.8
2022-08-11	-1.66	-1.87
2022-11-10	-1.53	-1.37

Oyster Point Pharma, Inc. (NASDAQ:OYST): Debt to assets
Dec 2021	222617000	123.08M	55.29%
Mar 2022	176720000	120.72M	68.32%
Jun 2022	143935000	133.16M	92.51%
Sep 2022	109201000	131.40M	120.33%

Oyster Point Pharma, Inc. (NASDAQ:OYST): Cash Flow
Dec 2021	-41.47M	-235K	50.91M
Mar 2022	-49.70M	-85K	-218K
Jun 2022	-38.83M	-118K	460K
Sep 2022	-35.97M	0	-166K

Oyster Point Pharma alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Oyster Point Pharma
Employees

Oyster Point Pharma, Inc. (NASDAQ:OYST): Employee count
Aug 2023	303
Sep 2023	303
Oct 2023	303
Nov 2023	303
Dec 2023	303
Jan 2024	303
Feb 2024	303
Mar 2024	303
Apr 2024	303
May 2024	303
Jun 2024	303
Jul 2024	303

Oyster Point Pharma
Insider Trading

Oyster Point Pharma, Inc. (NASDAQ:OYST): Insider trades (number of shares)
Period	Buy	Sel
Oct 2021	0	1650000

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	1 Nov 2021	LOCHNER DANIEL officer: Chief Financial Officer officer: Chief Financial Officer	Employee Stock Option (Right to Buy)	8,590	$11.51	$98,871
Option	1 Nov 2021	LOCHNER DANIEL officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	8,590	$11.51	$98,871
Option	21 Oct 2021	NAU JEFFREY director, officer..	Employee Stock Option (Right to Buy)	50,000	$1.02	$51,000
Option	21 Oct 2021	NAU JEFFREY director, officer..	Common Stock	50,000	$1.02	$51,000
Sale	18 Oct 2021	VERSANT VENTURE CAPITAL VI, L.P. 10 percent owner 10 percent owner	Common Stock	550,000	$14.86	$8,174,650
Sale	18 Oct 2021	OZAWA CLARE director, 10 percent owner director, 10 percent owner	Common Stock	550,000	$14.86	$8,174,650
Sale	18 Oct 2021	LINK WILLIAM J PHD director director	Common Stock	550,000	$14.86	$8,174,650
Option	2 Sep 2021	LOCHNER DANIEL officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	7,500	$11.51	$86,325
Option	2 Sep 2021	LOCHNER DANIEL officer: Chief Financial Officer officer: Chief Financial Officer	Employee Stock Option (Right to Buy)	7,500	$11.51	$86,325
Option	1 Sep 2021	NAU JEFFREY director, officer..	Common Stock	10,000	$1.02	$10,200

OYST insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application DRY EYE TREATMENTS Filling date: 6 Dec 2021 Issue date: 28 Jul 2022	6 Dec 2021	28 Jul 2022
Application	Application NESTING STRUCTURES FOR STORAGE, TRANSPORT, AND ASSEMBLY OF DRUG DISPENSERS AND CONTAINERS Filling date: 15 Jan 2021 Issue date: 21 Jul 2022	15 Jan 2021	21 Jul 2022
Application	Application COMBINATIONS OF POSITIVE ALLOSTERIC MODULATORS AND NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS FOR TREATING OCULAR CONDITIONS Filling date: 8 Jan 2021 Issue date: 9 Dec 2021	8 Jan 2021	9 Dec 2021
Application	Application SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE Filling date: 8 Jan 2021 Issue date: 2 Dec 2021	8 Jan 2021	2 Dec 2021
Grant	Grant Utility: Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine Filling date: 14 Aug 2019 Issue date: 16 Feb 2021	14 Aug 2019	16 Feb 2021
Application	Application METHODS OF TREATING OCULAR CONDITIONS Filling date: 17 Apr 2020 Issue date: 5 Nov 2020	17 Apr 2020	5 Nov 2020
Application	Application DRY EYE TREATMENTS Filling date: 10 Sep 2019 Issue date: 6 Aug 2020	10 Sep 2019	6 Aug 2020
Grant	Grant Utility: Methods of treating ocular conditions Filling date: 6 Apr 2017 Issue date: 14 Jul 2020	6 Apr 2017	14 Jul 2020
Application	Application SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE Filling date: 14 Aug 2019 Issue date: 2 Jul 2020	14 Aug 2019	2 Jul 2020
Grant	Grant Utility: Dry eye treatments Filling date: 1 Feb 2017 Issue date: 29 Oct 2019	1 Feb 2017	29 Oct 2019

Oyster Point Pharma
Earnings Call Transcripts

Quarter	Transcript
Q2 2022 13 Aug 2022	Q2 2022 Earnings Call Transcript
Q1 2022 8 May 2022	Q1 2022 Earnings Call Transcript
Q4 2021 27 Feb 2022	Q4 2021 Earnings Call Transcript
Q3 2021 7 Nov 2021	Q3 2021 Earnings Call Transcript

OYST earnings call transcripts

Oyster Point Pharma
Executives

Insider	Age	Compensation
Dr. Jeffrey Nau Ph.D., MMS (1975) Pres, Chief Executive Officer & Director	50	$833,600
Mr. Daniel Lochner M.B.A. (1983) Chief Financial Officer	42	$644,680
Mr. John Snisarenko M.B.A. (1964) Chief Commercial Officer	61	$604,680

Oyster Point Pharma
Latest News

Thursday, 10 November 2022
18:48	OYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue Estimates	Zacks Investment Research
Monday, 7 November 2022
20:53	Why Viatris (VTRS) Is Buying Oyster Point (OYST)	Pulse2
Wednesday, 2 November 2022
16:02	Oyster Point Pharma To Report Third Quarter 2022 Financial Results On November 10, 2022	GlobeNewsWire
Tuesday, 27 September 2022
08:00	Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII	GlobeNewsWire
Thursday, 25 August 2022
08:00	Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium	GlobeNewsWire
Saturday, 13 August 2022
15:45	Oyster Point Pharma, Inc. (OYST) CEO Dr. Jeffrey Nau on Q2 2022 Results - Earnings Call Transcript	Seeking Alpha
Thursday, 11 August 2022
18:49	OYSTER PT PHARM (OYST) Reports Q2 Loss, Lags Revenue Estimates	Zacks Investment Research
Monday, 8 August 2022
16:03	Oyster Point Pharma To Report Second Quarter 2022 Financial Results On August 11, 2022	GlobeNewsWire
Thursday, 21 July 2022
11:39	Wall Street Analysts Think OYSTER PT PHARM (OYST) Could Surge 423%: Read This Before Placing a Bet	Zacks Investment Research
Thursday, 30 June 2022
10:23	Oyster Therapeutics: State Of Business Is Confounding	Seeking Alpha
Sunday, 8 May 2022
05:15	Oyster Point Pharma, Inc.'s (OYST) CEO Dr. Jeffrey Nau on Q1 2022 Results - Earnings Call Transcript	Seeking Alpha
Thursday, 5 May 2022
18:48	OYSTER PT PHARM (OYST) Reports Q1 Loss, Tops Revenue Estimates	Zacks Investment Research
Tuesday, 3 May 2022
16:01	Oyster Point Pharma To Report First Quarter 2022 Financial Results On May 5, 2022	GlobeNewsWire
Sunday, 27 February 2022
13:35	Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q4 2021 Results - Earnings Call Transcript	Seeking Alpha
Thursday, 24 February 2022
20:46	OYSTER PT PHARM (OYST) Reports Q4 Loss, Tops Revenue Estimates	Zacks Investment Research
Wednesday, 16 February 2022
16:05	Oyster Point Pharma To Report Fourth Quarter And Full Year 2021 Financial Results On February 24, 2022	GlobeNewsWire
Tuesday, 21 December 2021
16:05	Oyster Point Pharma to Present at Upcoming Investor Conferences in January 2022	GlobeNewsWire
Tuesday, 9 November 2021
07:01	Oyster Point Pharma to Present Data at the American Academy of Ophthalmology Annual Meeting 2021	GlobeNewsWire
Sunday, 7 November 2021
01:05	Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q3 2021 Results - Earnings Call Transcript	Seeking Alpha
Tuesday, 2 November 2021
16:45	Oyster Point Pharma to Present Data at the American Academy of Optometry Annual Meeting 2021	GlobeNewsWire
Tuesday, 19 October 2021
11:26	Why Oyster Point Pharma Stock Is Sinking Today	The Motley Fool
Monday, 18 October 2021
17:36	FDA Approves First Nasal Spray For Dry Eye Disease From Oyster Point Pharma	Benzinga
08:09	OYST Stock: Why It Substantially Increased Today	Pulse2
Wednesday, 1 September 2021
17:24	Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 9 Nov 2022

Viatris: A Spinoff That Got Even More Interesting
Seeking Alpha 30 Jun 2022

Oyster Therapeutics: State Of Business Is Confounding
Seeking Alpha 24 Mar 2022

OKYO Pharma: Developer Of Next Generation Ocular Therapeutics

Frequently Asked Questions (FAQ)

When is Oyster Point Pharma's next earnings date?

Unfortunately, Oyster Point Pharma's (OYST) next earnings date is currently unknown.
Does Oyster Point Pharma pay dividends?

No, Oyster Point Pharma does not pay dividends.
What is Oyster Point Pharma's stock symbol?

Oyster Point Pharma, Inc. is traded on the NASDAQ under the ticker symbol "OYST".
What is Oyster Point Pharma's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Oyster Point Pharma?

Shares of Oyster Point Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Oyster Point Pharma's key executives?
Oyster Point Pharma's management team includes the following people:
- Dr. Jeffrey Nau Ph.D., MMS Pres, Chief Executive Officer & Director(age: 50, pay: $833,600)
- Mr. Daniel Lochner M.B.A. Chief Financial Officer(age: 42, pay: $644,680)
- Mr. John Snisarenko M.B.A. Chief Commercial Officer(age: 61, pay: $604,680)
How many employees does Oyster Point Pharma have?

As Jul 2024, Oyster Point Pharma employs 303 workers.
When Oyster Point Pharma went public?

Oyster Point Pharma, Inc. is publicly traded company for more then 5 years since IPO on 31 Oct 2019.
What is Oyster Point Pharma's official website?

The official website for Oyster Point Pharma is oysterpointrx.com.
Where are Oyster Point Pharma's headquarters?

Oyster Point Pharma is headquartered at 202 Carnegie Ctr Ste 109, Princeton, NEW JERSEY.
How can i contact Oyster Point Pharma?

Oyster Point Pharma's mailing address is 202 Carnegie Ctr Ste 109, Princeton, NEW JERSEY and company can be reached via phone at +1 609 382 9032.

Oyster Point Pharma, Inc.

oysterpointrx.com

Exchange:

NASDAQ

Full time employees:

303

Industry:

Biotechnology

Sector:

Healthcare

As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

+1 609 382 9032

202 Carnegie Ctr Ste 109
Princeton, NEW JERSEY 08540

CIK: 0001720725
ISIN: US69242L1061
CUSIP: 69242L106